Innoviva to Participate in Cantor Fitzgerald’s Global Healthcare Conference on September 26
September 21 2017 - 4:15PM
Business Wire
Innoviva, Inc. (NASDAQ: INVA) today announced that Michael W.
Aguiar, Innoviva's President and Chief Executive Officer
and Eric d’Esparbes, SVP and Chief Financial Officer will present
at the Cantor Fitzgerald Global Healthcare Conference on
Tuesday, September 26 at 4:35 EDT, at the InterContinental New York
Barclay Hotel in New York City.
The presentation will be webcast live and archived for 90 days.
Please follow the link below or visit the IR section of the
Innoviva website to view the presentation:
http://wsw.com/webcast/cantor6/inva
About Innoviva
Innoviva is focused on bringing compelling new medicines to
patients in areas of unmet need by leveraging its significant
expertise in the development, commercialization and financial
management of bio-pharmaceuticals. Innoviva's portfolio is anchored
by the respiratory assets partnered with Glaxo Group Limited (GSK),
including RELVAR®/BREO® ELLIPTA® and ANORO® ELLIPTA®, which were
jointly developed by Innoviva and GSK. Under the agreement with
GSK, Innoviva is eligible to receive associated royalty revenues
from RELVAR®/BREO® ELLIPTA®, ANORO® ELLIPTA®. In addition, Innoviva
retains a 15 percent economic interest in future payments made by
GSK for earlier-stage programs partnered with Theravance BioPharma,
Inc., including the closed triple combination therapy for Chronic
Obstructive Pulmonary Disease (COPD). For more information, please
visit Innoviva's website at www.inva.com.
ANORO®, RELVAR®, BREO® and ELLIPTA® are trademarks of the
GlaxoSmithKline group of companies.
View source
version on businesswire.com: http://www.businesswire.com/news/home/20170921006143/en/
Innoviva, Inc.Eric d'EsparbesSenior Vice President and Chief
Financial Officer650-238-9640investor.relations@inva.com
Innoviva (NASDAQ:INVA)
Historical Stock Chart
From Aug 2024 to Sep 2024
Innoviva (NASDAQ:INVA)
Historical Stock Chart
From Sep 2023 to Sep 2024